Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

NCT04814485 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: SHR-1020+albumin-bound paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital